SHIFT Newsroom · UK

MHRA Warns of Potential Risk of Pulmonary Aspiration with GLP-1 and Dual GIP/GLP-1 Receptor Agonists

By SHIFT AI Newsroom · Published 10 September 2026

How we prepare and check newsroom articles · Report a correction

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update regarding the potential risk of pulmonary aspiration during general anaesthesia or deep sedation with GLP-1 and dual GIP/GLP-1 receptor agonists. This update is relevant to UK patients and healthcare professionals who use or prescribe these medicines.

SHIFT’s take

What we think this could mean for you, and what remains uncertain.

This update is relevant to UK patients and healthcare professionals who use or prescribe GLP-1 and dual GIP/GLP-1 receptor agonists, as it highlights a potential risk associated with their use during general anaesthesia or deep sedation

Known facts

The MHRA has issued a drug safety update regarding the potential risk of pulmonary aspiration with GLP-1 and dual GIP/GLP-1 receptor agonists

Sources and evidence

MHRA — Source date: 28 January 2025

← Back to SHIFT Newsroom